Side effects and changes in pulmonary function after fixed dose precurarization with alcuronium, pancuronium or...

Area of Science:

• Anesthesiology
• Pharmacology

Background:

• Neuromuscular blocking agents are used in anesthesia.
• Precurarization aims to mitigate side effects of subsequent drugs.
• Suxamethonium can cause undesirable side effects.

Purpose of the Study:

• To compare the effects of alcuronium, pancuronium, and vecuronium on pulmonary function.
• To assess the efficacy of these agents in preventing suxamethonium-associated side effects.
• To determine if fixed-dose precurarization impacts pulmonary function.

Main Methods:

• 160 surgical patients received premedication.
• Fixed doses of alcuronium (2 mg), pancuronium (1 mg), or vecuronium (1 mg) were administered.
• Pulmonary function and signs of neuromuscular blockade were monitored.
• Comparison of drug efficacy in preventing suxamethonium side effects.

Main Results:

• No significant differences were found in preventing suxamethonium side effects among the three drugs.
• Alcuronium and pancuronium caused minor decreases in pulmonary function.
• Vecuronium (1 mg) resulted in statistically significant reductions in pulmonary function.

Conclusions:

• Alcuronium, pancuronium, and vecuronium are equally effective in preventing suxamethonium side effects.
• Fixed-dose precurarization with vecuronium may lead to significant pulmonary function changes.
• Careful consideration of pulmonary effects is needed when using vecuronium for precurarization.